haematological cancer

This page shows the latest haematological cancer news and features for those working in and with pharma, biotech and healthcare.

Keytruda hits primary endpoint in confirmatory lymphoma trial

It was the first green light for the drug in a haematological cancer, and Keytruda has since gone on to receive approval in primary mediastinal B-cell lymphoma, a rare form ... Patients with classical Hodgkin lymphoma are generally young and when they do

Latest news

AstraZeneca’s Calquence impresses in previously untreated CLL

broad range of haematological cancer indications.
AstraZeneca wins FDA approval for Calquence in chronic lymphoma

range of haematological cancer indications.
Roche agrees $1.4bn takeover of fibrosis specialist Promedior

That mechanism suggests PRM-151 could have potential in a range of diseases characterised by fibrosis, including myelofibrosis – a haematological cancer that results in scarring of the bone marrow and severe ... With our proven track record in IPF with
AZ’s Calquence threatens Imbruvica with new leukaemia data

blockbuster product with sales of $3.6bn in 2018 and a target of $4.4bn this year across a broad range of haematological cancer indications.
Celgene boosts haematology pipeline with $7bn Impact Bio deal

and downgraded sales estimates for its haematological cancer drugs.

More from news
Approximately 2 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Deal Watch September 2016

Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological malignancies. ... Adaptimmune Therapeutics entered into a collaboration with MD Anderson Cancer Center to develop specific